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Gankyrin is an ankyrin-repeat oncoprotein whose overexpression has been implicated in the 
development of many cancer types. Elevated gankyrin levels are linked to aberrant cellular events 
including enhanced degradation of tumour suppressor protein p53, and inhibition of gankyrin activity 
has therefore been identified as an attractive anticancer strategy. Gankyrin interacts with several 
partner proteins, and a number of these protein-protein interactions (PPIs) are of relevance to 
cancer. Thus, molecules that bind the PPI interface of gankyrin and interrupt these interactions are of 
considerable interest. Herein, we report the discovery of a small molecule termed cjoc42 that is capable 
of binding to gankyrin. Cell-based experiments demonstrate that cjoc42 can inhibit gankyrin activity in 
a dose-dependent manner: cjoc42 prevents the decrease in p53 protein levels normally associated with 
high amounts of gankyrin, and it restores p53-dependent transcription and sensitivity to DNA damage. 
The results represent the first evidence that gankyrin is a “druggable” target with small molecules.
Repeat proteins, such as ankyrin, leucine-rich, HEAT and tetratricopeptide repeats, are a distinctive class of 
proteins comprising tandem arrays of small structural motifs that stack in a linear manner to form elongated 
architectures. Gankyrin is an ankyrin-repeat oncoprotein1,2 with potent cell-cycle stimulatory and anti-apoptotic 
properties that is overexpressed early in hepatocellular carcinoma (HCC) and whose upregulation is associated 
with poor prognosis in esophageal squamous cell carcinoma (ESCC), glioblastomas, colorectal, pancreatic and 
lung carcinomas3–5. Existing treatment options for these cancers are limited, and no small-molecule inhibitors of 
gankyrin have been published to date; a broad-spectrum histone deacetylase inhibitor LBH589 is known to affect 
the proliferative and metastatic potential of gankyrin over-expressing HCCs, but it lacks selectivity6. Inhibitors of 
gankyrin are expected to have a negative effect on tumour formation and growth (indeed, inhibition of gankyrin 
expression by siRNA has been shown to have such effects both in vitro and in vivo4,6,7), and gankyrin is therefore 
regarded as a promising target for potential anticancer therapeutic agents8,9.
Gankyrin is composed of seven helix-turn-helix-loop ankyrin modules, which together generate a relatively 
featureless concave surface (Fig. 1a)1,2,10. This surface is presumed to be the interface through which gankyrin 
contacts several physiological binding partners. A number of these protein-protein interactions (PPIs) are known 
to be of relevance to cancer. For example, gankyrin enhances the phosphorylation of tumour suppressor protein 
pRb by binding to cyclin-dependent kinase 4 (CDK4) and abrogating CDK4 inhibition by tumour suppressor 
protein p16NK4a (referred to subsequently as p16). Gankyrin also binds to the ubiquitin ligase MDM2 and 
enhances the ubiquitination of p538,9,11,12. Additionally, gankyrin is one of a number of repeat-protein “chap-
erones” required for the assembly of the proteasome regulatory particle. It binds the S6 ATPase subunit (also 
known as rpt3) of this particle13, and it is thought that through this interaction it further enhances the targeting 
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of p53 (and possibly of pRb also) to the proteasome for degradation. Thus, gankyrin PPIs serve to modulate the 
destruction of principal tumour suppressor proteins p53 and pRb. Gankyrin overexpression results in decreased 
cellular levels of these two key proteins, leading ultimately to the onset of oncogenic cell functions and fate11,14,15. 
Modulation of disease-associated gankyrin activity will require physical disruption or inhibition of its PPIs, and 
this has been identified as an attractive therapeutic strategy for the treatment of numerous cancer types. Agents 
that are capable of binding the PPI surface of gankyrin would be of considerable value not only as potential 
starting points for the development of new cancer treatments but also as tools with which to further delineate the 
mechanisms of gankyrin function. Chapman and McNaughton have recently reported the synthesis of resurfaced 
proteins whose shapes are complementary to the putative PPI face of gankyrin; these proteins selectively bind to 
gankyrin10 and modulate its activity in vitro14. However, no selective, direct small-molecule binders of gankyrin 
capable of modulating gankyrin activity within a cancer cell are currently known. If such drug-like molecules 
could be identified they would ultimately have greater therapeutic potential than engineered proteins due to their 
small size and ease of cell penetration. Thakur and co-workers have reported computational modelling studies 
directed towards the design of a potent ligand to inhibit the activity of gankyrin, but these molecules were not 
experimentally validated7.
Herein, we report the discovery of a small molecule (designated “cjoc42”, Fig. 1b) that is capable of binding 
to (human) gankyrin. Our data suggest that cjoc42 targets the proposed PPI binding surface of gankyrin at the 
region where the protein interacts with the C-terminal portion of the S6 binding partner (referred to as S6C 
herein; the atomic structure of the complex between mouse gankyrin (mGankyrin) and S6C is known and shows 
that S6C binds to the concave face of gankyrin13; see Fig. 1a and Supplementary Fig. S1). In human osteosarcoma 
U2OS cells overexpressing gankyrin, low micromolar concentrations of cjoc42 prevented the decrease in p53 
protein levels normally associated with high amounts of gankyrin, restored p53-dependent transcription and 
sensitivity to DNA damage. These results provide proof-of-principle that a small molecule targeting the PPI sur-
face of gankyrin is able to modulate gankyrin activity in the cell. Small molecules of this kind should be useful as 
chemical probes with which to dissect further mechanistic details of gankyrin’s function. Of wider significance, 
these findings provide the first proof that gankyrin is a druggable target with small molecules.
Results
Screening small molecules for gankyrin binding using a thermal shift assay. Small molecules 
from diversity-oriented synthesis (DOS) libraries generated in-house were screened in a thermal shift assay to 
determine their ability to bind gankyrin16. Experiments were performed at a protein concentration of 20 μM and 
a compound concentration of 300 μM. Primary hits were identified as compounds causing an increase in melt-
ing temperature ≥ 0.5 °C. The screening process led to the identification of a hit molecule, designated as cjoc42 
(Fig. 1b). See Supplementary Fig. S2 for thermal shift assay data.
Analysis of the gankyrin-cjoc42 interaction. Thermodynamic characterization of the gankyrin-cjoc42 
interaction. Label-free microscale thermophoresis (MST) was employed to determine the affinity of cjoc42 
for gankyrin. Using this method, a dissociation constant (Kd) of 630 ± 40 nM was obtained (Fig. 2a). Given the 
Figure 1. Relevant structures. (a) Schematic of the structure of gankyrin (in colour) complex with S6C.  
(b) Chemical structure of cjoc42.
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relevance of the gankyrin-S6 interaction to cancer, we were interested in exploring the possibility that cjoc42 and 
S6 bind to the same region of gankyrin. It is not possible to express S6C (or even full-length S6) in isolation from 
gankyrin (in a non-grafted form), as it appears that S6 must be bound to gankyrin to remain in solution10. Instead, 
cjoc42 was titrated into the preformed complex of gankyrin and S6C. No detectable binding was observed, and 
this result suggests that the binding sites on gankyrin for cjoc42 and S6C overlap with each other (Fig. 2a).
The interaction between cjoc42 and gankyrin was also measured using isothermal calorimetry (ITC, Fig. 2b), 
and values for the Kd of 580 ± 70 nM and stoichiometry of 0.8 ± 0.1 were obtained. To investigate the specific-
ity of the interaction, cjoc42 was titrated into the ankyrin-repeat protein p16, which has sequence similarity to 
gankyrin and which like gankyrin also binds to CDK4. p16 had no detectable affinity for cjoc42 (not shown).
A focused library of 12 analogues of cjoc42 (compounds 1–12, Fig. 3, see Supplementary Information for 
synthetic procedures) was then generated to explore the chemical space around the hit scaffold.
In addition to three alternative sulfonic esters, the compound set also included nine sulfonamides. These 
varied in: (i) the nature of the substituent on the phenyl ring linked directly to the triazole ring (methyl ester 
in 4,5,10–12, free acid in 6–7 and amide in 8–9); (ii) the length of the linker between the triazole ring and the 
sulfonamide amine (compare 4–10 to 11–12); (iii) the alkylation state of the sulfonamide nitrogen (compare 6–7 
with 4,5,8–12); and (iv) the nature of the aromatic portion of the sulfonamide moiety (para-tolyl in 4–9 and 11, 
naphthyl in 10 and 12). The cjoc42 analogues (and late-stage synthetic intermediates) were subsequently screened 
using ITC to determine their affinities for gankyrin. Of these compounds only 8 and 12 were found to have mod-
erate binding affinities to gankyrin (Kd values of approximately 10 μM and 56 μM, respectively, as determined by 
ITC, see Supplementary Fig. S3 and S4, respectively). In addition to these analogues, a series of tosylate fragments 
were screened, based on the premise that the sulfone portion of cjoc42 may be a significant contributor to its over-
all binding affinity for gankyrin (see Supplementary Figs S5–S8). However, all the tosylate fragments were found 
to bind very weakly (Kd values greater than 200 μM as determined by ITC, see Supplementary Fig. S4). Overall, 
Figure 2. Thermodynamic characterization of the gankyrin-cjoc42 interaction. (a) Titration of cjoc42 into 
gankyrin and the gankyrin-S6C preformed complex, measured by MST. The protein concentration was 5 μM. 
(b) ITC trace of cjoc42 (100 μM) titrated into gankyrin (10 μM).
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none of the compounds examined were found to have a stronger binding affinity for gankyrin than did cjoc42. 
Thus, attention turned towards further biophysical analysis of the binding of cjoc42 to gankyrin.
NMR analysis of the gankyrin-cjoc42 interaction. The previously reported solution NMR structure of gankyrin2 
was used to obtain information about the binding interface of cjoc42 on gankyrin (Fig. 4). NMR data showed 
changes in both chemical shifts and line broadening for a subset of gankyrin residues in the presence of cjoc42, 
which, when mapped onto the structure, reveal a number of solvent-exposed clusters located along the concave 
surface at which S6C binds (Fig. 4).
The fact that we observe by ITC an approximate 1:1 stoichiometry for the gankyrin-cjoc42 interaction sug-
gests that cjoc42 binds to one site rather than multiple sites; the delocalized nature of the residues found by NMR 
to be perturbed in the presence would then indicate that the effect of cjoc42 binding at one site is propagated to 
distant sites throughout the protein’s length. This finding is consistent with long-range effects of ligand binding 
that have previously been observed both for repeat proteins17,18 and for numerous other proteins19–23.
In silico analysis of the gankyrin-cjoc42 interaction. The NMR experiments showed chemical shift changes and 
line broadening of clusters of solvent-exposed residues of gankyrin in the presence of cjoc42. To further delin-
eate the cjoc42-binding site on gankyrin, molecular docking was carried out in an unbiased approach (blind 
docking) with three independent docking algorithms (AutoDock Vina, AutoDock 4.2 and EADock DSS) applied 
with multiple repeats (Fig. 5 and Supplementary Figs S9 and S10). By overlaying the docked structure with the 
gankyrin-S6C crystal structure (Supplementary Fig. S11) we can see that the top-ranked poses (i.e. the ones with 
the lowest free energy of binding) in all of the runs showed cjoc42 docking onto a region of the gankyrin surface 
at which S6C makes contacts via the latter’s exposed loops (specifically S6 residues 355SEEVD359 and 393I-L395) 
(Fig. 5a and Supplementary Fig. S11). The electronegative EEVD loop interacts predominantly with an elec-
tropositive patch on the surface of gankyrin. Supplementary Fig. S11 shows that cjoc42 overlays on this loop and 
docks close to the electropositive patch of gankyrin.
Ligand interaction diagrams constructed using PLIP (Fig. 5b) and LigPlus (Fig. 5c) show that the two nitrogen 
atoms from the triazole ring engage in hydrogen bonding with the phenolic hydroxy group of Tyr 15. The indole 
ring of Trp74 and the aromatic ring of the tosylate moiety of cjoc42 engage in a π -π stacking interaction, whilst 
the sulfonyl oxygen of the tosylate group forms hydrogen bonds with the amino group of Lys116 and hydroxyl 
group of Ser82. The phenyl ring linked directly to the triazole ring appears also to engage in a π -π stacking inter-
action with the indole ring of Trp46.
Inspection of the docked cjoc42 pose shows that the tosyl group of cjoc42 is positioned in such a way as to 
serve as surrogate for the carbonyl groups of Glu356 and Glu357 of the S6 355SEEVD359 motif. The aromatic 
Figure 3. Analogues of cjoc42. See Supplementary Information for full synthetic details.
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methyl-phenyl moiety of cjoc42 is poised similarly to mimic the Val358 of the S6 355SEEVD359 motif. The other 
phenyl group of cjoc42 (that is linked directly with the triazole ring) is poised similarly to mimic residue Leu395 
of S6 (Supplementary Fig. S11). Thus some atoms of cjoc42 in its docked pose mimic the spatial distribution 
of the critical residues of the exposed loop of S6C that interact with mGankyrin, adopting a 3D shape that 
is largely complementary to the local cavity (Supplementary Fig. S9). It is worth noting that this site (i.e. the 
cjoc42-interacting site on hGankyrin/the S6 ‘SEEVD’-interacting site on mGankyrin) is predicted by FTMap24 
as the most likely hot-spot on the gankyrin surface for interaction with small molecules or proteins. Indeed, a 
number of proteins, which, like S6, have an EEVD motif, were recently shown to interact with gankyrin25. Given 
the electropositive/electroneutral nature of the site, as shown in the surface electrostatics representation (Fig. 5d), 
it seems entirely plausible that electronegative EEVD peptides as well as the sulfonyl group of the cjoc42 can be 
accommodated there.
Control experiments. A number of control experiments were carried out to address the possibility of cjoc42 
being a false positive hit from the thermal shift screen (see Supplementary Information). Mass spectrometry was 
used to test for the possibility of the binding observed in our biophysical assays being due to a covalent attach-
ment between gankyrin and cjoc42. Time-of-flight (TOF) electrospray mass spectrometry spectra of gankyrin 
alone (50 μM) and gankyrin (50 μM) incubated with cjoc42 (300 μM) showed a single major peak corresponding 
to the molecular weight of unconjugated gankyrin (see Supplementary Fig. S12). No peak corresponding to alky-
lated protein was observed, indicating that cjoc42 does not bind in a covalent manner to gankyrin. Compound 
cjoc42 at a concentration of 200 μM was found to have no effect on two unrelated and well-characterized PPIs 
(Rad51-BRC4 and Aurora A-TPX2) in a fluorescence polarization assay (see Supplementary Fig. S13), indicating 
that cjoc42 does not show non-specific binding. In addition, before optimizing the cellular assays that used the 
osteosarcoma U2OS cell line as a model system (vide infra), potential system-wide effects of cjoc42 addition to 
U2OS cells were investigated. No changes in mitotic index (see Supplementary Fig. S14) or cell viability (see 
Supplementary Fig. S15) were observed (compound concentrations up to 50 μM), indicating that any observed 
changes that might result from the addition of cjoc42 are unlikely to be due to non-specific adverse effects related 
to cell proliferation or toxicity.
Figure 4. NMR analysis of the gankyrin-cjoc42 interaction. (a) Changes in cross-peak intensity of the amide 
backbone of gankyrin in the presence of cjoc42. (b) Changes in chemical shifts of the amide backbone of 
gankyrin in the presence of cjoc42. (c) Residues 16, 38, 107, 108, 117, 169, 170, 183, with chemical shift changes 
(Δδ (15N-1H)) of > 0.01 that also show significant intensity changes in the presence of cjoc42, are shown on the 
gankyrin structure.
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Cellular activity of cjoc42. Collectively, the biophysical experiments strongly indicated that cjoc42 binds 
to the putative PPI interface of gankyrin at the region where the protein interacts with the S6 binding partner. We 
turned our attention next towards evaluating the cellular activity of cjoc42 by determining its effect on p53 levels 
and activity in the osteosarcoma U2OS cell line as a model system.
cjoc42 counteracts gankyrin-induced decrease in p53 protein levels. The effects of cjoc42 in gankyrin-overexpressing 
cells were first examined. FLAG-tagged gankyrin over-expression was first optimised in the (p53 normal) osteo-
sarcoma cell line U2OS to enable the detection of small changes in intracellular protein levels in whole cell lysates 
48 hours post transfection, a significant reduction in p53 levels could be detected without any change in the levels 
of housekeeping protein β -actin (Fig. 6a). When the gankyrin-overexpressing cells were incubated with cjoc42, 
a dose-dependent restoration of p53 levels (comparable to mock transfected cells) could be seen. There was no 
significant change in p53 levels when cells were treated with cjoc42 alone without gankyrin (Fig. 6b). Thus, it can 
be concluded that cjoc42 is capable of inhibiting gankyrin-induced lowering of p53 levels in cells.
It was found that p53 levels are also affected by the addition of cjoc42 in the liver cancer cell line HepG2 where 
gankyrin expression is a key oncogenic driver, indicating that the compound can affect endogenous gankyrin in 
a manner similar to that observed for gankyrin over-expressed by transfection (Supplementary Fig. S16). Thus, 
with a view to studying the effects of the compound in a cellular environment with normal p53 background and 
where gankyrin expression (+ /− ) and levels can be modulated at will, we chose to perform the subsequent func-
tional assays in the transfection-amenable cell line U2OS. We further found that cjoc42 does not alter the mRNA 
levels of p53 or housekeeping genes like GAPDH (Supplemental Fig. S17), indicating that the compound does not 
exert its cellular effect on p53 at the level of transcription.
cjoc42 inhibits gankyrin-induced decrease in p53 luciferase reporter activity. A p53 luciferase reporter assay was 
used to examine the downstream consequences of reduction in p53 protein levels due to gankyrin overexpres-
sion. Reduced p53 levels lead to a decrease in the binding of p53 to its cognate site on a co-transfected luciferase 
reporter construct, which results in reduction of luciferase activity compared to mock-transfected cells. The addi-
tion of cjoc42 to gankyrin-overexpressing U2OS cells was able to prevent this reduction of luciferase activity. This 
result suggests that gankyrin-mediated decrease in p53 reporter binding is inhibited by the presence of cjoc42. 
Addition of cjoc42 alone did not affect reporter activity when compared with mock-transfected cells, confirming 
that the effect of cjoc42 is gankyrin-dependent (Fig. 6c).
Figure 5. In silico analysis of the gankyrin-cjoc42 interaction. (a) The docking site of cjoc42 on gankyrin 
(pdb 1QYM) with a close-up of the interacting interface shown above. The pose represents the top ranked (i.e. 
lowest energy, ∆ G = − 6.3 kcal/mol) pose obtained from blind docking using AutoDock Vina. Similar results 
were obtained using AutoDock 4.2 and EADock DSS. (b,c) Ligand interaction diagram of the docked pose of 
cjoc42 on gankyrin. The diagrams were generated using PLIP (b) and LigPlot+ (c). (d) The electrostatic surface 
potential representation of gankyrin with cjoc42 docked onto it. Red, blue, and white represent acidic, basic, and 
neutral (hydrophobic) regions, respectively, with the sliding colour scale (± 5 kTe−1, where k is the Boltzmann 
constant, T is temperature and e is the elementary charge) below indicating the charge distribution across the 
gankyrin surface.
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cjoc42 inhibits gankyrin-induced decrease in p53 downstream target expression and resensitises cells to DNA dam-
age. Etoposide concentrations were first optimized at 0.2 μM to trigger DNA damage, resulting in loss of cell via-
bility. Next, assays were performed using these conditions, for gankyrin-transfected or mock-transfected U2OS 
cells with simultaneous cjoc42 incubation. Gankyrin-transfected cells showed a modest reduction in the levels of 
p21 (a p53 downstream target) expression, which was restored upon cjoc42 addition (Fig. 7a). Mock-transfected 
cells did not show significant changes in p21 expression when exposed to cjoc42 (Fig. 7a). Both the Trypan 
blue dye exclusion assay (Invitrogen) and the Cell Titre Glo cell viability assay (Promega) showed that there 
was enhanced cell viability for gankyrin-transfected cells compared to mock-transfected cells. Simultaneous 
Figure 6. Cellular activity of cjoc42 (abbreviated to ‘42’). In (a,b) the left-hand figures show representative 
images and the right-hand figures show densitometry analysis of band intensities (n = 3 and SEM). All data 
were normalized to untreated mock-transfected cells, and all statistical comparisons (t tests) were made to 
these. ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; (a) Effects of gankyrin over-expression on levels of 
p53 and β -actin in U2OS cells 48 hours post transfection with 2 μg gankyrin plasmid, p53 expression levels are 
reduced by ~40% compared with control cells. cjoc42 (abbreviated to ‘42’) addition at the time of transfection 
inhibits this decrease in p53 levels. (b) Cells treated with cjoc42 alone do not show any changes in p53 levels 
compared to mock transfections. (c) Reduction of p53 luciferase reporter activity in gankyrin-overexpressing 
U2OS cells can be inhibited by cjoc42 (abbreviated to ‘42’) in a dose-dependent manner. cjoc42 alone at 
equivalent doses does not alter the luciferase reporter activity.
www.nature.com/scientificreports/
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incubation with cjoc42 was able to restore sensitivity to DNA damage (as indicated by lower cell viability) in the 
gankyrin-overexpressing cells in a dose-dependent manner (Fig. 7b). Cells incubated with cjoc42 alone showed 
no dose-dependent change in cell viability, indicating that the loss in cell viability induced by cjoc42 is mediated 
by gankyrin.
Discussion
Herein, we report the discovery of cjoc42, a novel small molecule that is capable of binding directly to the onco-
protein gankyrin. Cell-based experiments showed that cjoc42 is not toxic. In cells overexpressing gankyrin, cjoc42 
in a dose-dependent manner prevents the decrease in p53 protein levels normally associated with high amounts 
of gankyrin, and it restores p53-dependent transcription and sensitivity to DNA damage. Our data suggest that 
cjoc42 targets the proposed PPI interface of gankyrin in the region where the protein interacts with its binding 
partner S6; the compound does not appear to modulate PPIs non-specifically. Thus cjoc42 represents the first 
selective small-molecule binder and modulator of gankyrin activity, and our study provides proof-of-principle 
that small molecules that target the PPI surface of gankyrin are able to inhibit its cellular function.
Gankyrin is a central regulatory hub for numerous proteins involved in p53 and pRb tumour suppressor path-
ways. Neither the locations of the binding sites for these proteins on gankyrin nor the dynamics between them in 
vivo are known; however, given that cjoc42 produces a cellular effect at low micromolar concentrations, we pro-
pose that cjoc42 binds to and increases the pool of intracellular gankyrin that is not complexed with S6; cjoc42 is 
thereby simultaneously able to block and/or disrupt interactions of this surface with partner proteins too. Of note 
in this regard, McNaughton and colleagues recently reported the attenuation of the ubiquitination function of 
the gankyrin-MDM2 complex in vitro upon addition of a synthetic gankyrin-binding protein designed to mimic 
S6C14, but in the absence of structural information about the gankyrin-MDM2 complex it is unclear how this 
S6-mimetic protein achieves this effect. Compound cjoc42 represents a small-molecule starting point that targets 
the S6-binding interface of gankyrin and that is able to enhance p53 levels and activity in the cell, likely doing so 
by modulating the relative compositions of gankyrin complexes with its various partner proteins and shifting the 
equilibrium between them. Compound cjoc42 is thus both a valuable chemical probe with which to investigate 
the spatio-temporal sequence and dynamics of such gankyrin-partner protein complex formation and also a 
starting point for the development of a small-molecule anticancer therapy directed against gankyrin.
Methods
Protein expression. The E. coli expression construct for His-tagged full-length human gankyrin was a kind 
gift from A. J. Wilkinson (University of York, UK). The protein was purified as described previously1. The genes 
encoding human gankyrin and S6C were cloned into pETDuet1 (Novagen). The complex was purified as previ-
ously described13. The buffer used in all subsequent experiments was 20 mM sodium borate buffer, pH 7.5, unless 
stated otherwise.
Thermal shift assay. The thermal shift assay was performed in a 96-well plate with 20 μM gankyrin in buffer 
containing Sypro Orange (Invitrogen). Compounds were added, from a master stock of 10 mM to obtain a final 
Figure 7. cjoc42 (abbreviated to ‘42’) inhibits gankyrin-induced decrease in p53 downstream target 
expression and resensitises cells to DNA damage. (a) Four hours after DNA damage with Etoposide a 
reduction of p21 upregulation is seen in gankyrin-overexpressing U2OS cells (lane 2) compared to mock 
transected cells (lane 1). This can be prevented by cjoc42 addition (lane 3). cjoc42 alone shows upregulation 
of p21 (in the presence of DNA damage) to levels comparable with mock-transfected cells (lane 4). (b) Cell 
viability (expressed as a percentage of control) 24 hours after Etoposide treatment. Gankyrin-overexpressing 
U2OS cells incubated with cjoc42 show a dose-dependent loss of viability. Cells not expressing gankyrin  
(— Gankyrin) show no such dose-dependent change in cell viability.
www.nature.com/scientificreports/
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concentration of 300 μM, keeping the DMSO concentration at 5% vol/vol in all wells. All measurements were 
done in triplicates. Unfolding of gankyrin was monitored between 15 °C and 65 °C and melting curves were gen-
erated by plotting SYPRO Orange fluorescence as a function of temperature. The resulting data were fitted to 
obtain the melting temperature Tm (point of sigmoidal inflection) as the maximum of each curve’s derivative. A 
hit was defined as a compound that increased the Tm by at least 0.5 °C.
Microscale thermophoresis (MST). MST measurements were made using the Monolith NT.Label.Free 
device with standard treated capillaries (NanoTemper Technologies) and the manufacturer’s standard settings 
(Laser-power 20%, Laser-on time 60s, LED power 20%). Measurements were performed in 20 mM Na-Borate 
buffer, pH 7.5, 10% DMSO. The relative change in fluorescence intensity due to thermophoresis was measured 
by varying the concentration of cjoc42 (a 1:1 serial dilution series) against a fixed concentration of gankyrin or 
gankyrin-S6C complex (5 μM).
Isothermal titration calorimetry (ITC). Gankyrin samples were dialysed overnight into 20 mM sodium 
borate buffer pH 7.5. cjoc42 (or other compounds) solution was adjusted to the appropriate concentration using 
the same dialysis buffer. DMSO concentration was added to 5% vol/vol (final) for both protein and compound 
samples. ITC measurements were performed at 25 °C on a Microcal VP ITC calorimeter (Malvern, UK) with 
gankyrin in the sample chamber and compound added via the syringe using 30 successive additions of 10 μl for 
12 s (with an initial injection of 5 μl for 6 s). The interval between each injection was 240 s. Data were analysed 
using the instrument’s ORIGIN analysis software.
NMR spectroscopy analysis of the gankyrin-cjoc42 interaction. NMR samples comprised 100 μM 
gankyrin in buffer containing 5% dimethyl sulfoxide (DMSO), 10% D2O and 0.01% 4, 4-dimethyl-4-silapentane-1
-sulfonic acid (DSS). Cjoc42, when included, was at a concentration of 100 μM. 2D 1H-15N HSQCs were moni-
tored at 300 K on a Bruker Avance 700 MHz Ultrashield spectrometer equipped with a TXI cryoprobe. NMR data 
were processed using NMRPipe26 and analyzed using Sparky. The changes in chemical shift (Δδ (15N-1H)) and 
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where δGankyrin(15N), δGankyrin(1H) δGankyrin+042(15N) and δGankyrin+042(1H) are the 15N and 1H chemical shifts of the 
peptide amide group of each residue of gankyrin when the protein in the absence and presence of cjoc42, and 
IGankyrin and δGankyrin+042 are the intensities of the peptide amide group of each residue of gankyrin in the absence 
and presence of cjoc42.
In silico methods. Docking experiments were performed using a blind docking approach and several soft-
ware packages based on different algorithms. These include AutoDock Vina version 1.1.2 (http://vina.scripps.
edu/)27, AutoDock 4.2 (http://autodock.scripps.edu/) and EADock DSS implemented in the SwissDock server 
(http://www.swissdock.ch/)28. In each case, docking was performed as three independent runs to assess repro-
ducibility and only the lowest energy pose was considered for each case. For detailed inspection and analyses of 
the docked poses, ligand interaction diagrams were generated using LigPlot + version 1.429 and Protein-ligand 
interaction profiler (PLIP)30. FTMAP server (http://ftmap.bu.edu/)24 was used for predicting the hot spots for 
ligand binding on the gankyrin surface.
Cell culture, gankyrin overexpression and DNA damage. U2OS cells were grown using standard 
cell culture conditions as described in Higashitsuji9 and with the same FLAG-gankyrin overexpression vector 
(Agilent Technologies, Santa Clara, CA) kindly provided by Dr J. Fujita (Japan). Cells were transiently trans-
fected with 2 μg of this construct using Lipofectamine 200 (Life Technologies) with 1 × 106 cells per transfection. 
Gankyrin, p53, p21 and β -actin expression levels were subsequently assessed at 24–72 h by Western blot both with 
and without incubation of varying concentrations of cjoc42 that had been freshly dissolved in 0.5% DMSO (final). 
DNA damage, where necessary, was induced with 0.2 μM etoposide treatment, 24 hours post gankyrin transfec-
tion. Control transfections were performed simultaneously using 2μg pmaxGFP expression vector (Amaxa) to 
determine transfection efficiency.
p53 luciferase reporter assay. U2OS cells were plated at 2 × 104 cells/well of a 96 well plate 1 day before 
the transfection. The p53 promoter-reporter plasmid PGL4.38 (Promega), an internal control plasmid, pRL-TK 
(Promega) and the FLAG-gankyrin expression plasmid, were co-transfected into cells the next day with or with-
out the addition of cjoc42 in DMSO (1 μM final concentration). Control wells had 1% DMSO alone. The cells 
were harvested for the luciferase assay 48 hours post transfection. Luciferase activity was measured by using 
the dual-luciferase reporter assay system (Promega) following the manufacturer’s instructions. The results 
were analysed as the fold induction of the reporter plasmid alone after normalization with the internal con-
trol plasmid pRL-TK for each transfection condition, and they are presented as normalized change relative to 
mock-transfected cells.
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Cell viability assay. Cell viability was assessed using the Cell Titre Glo assay (Promega) coupled to a Tecan 
Infinite F200 microplate reader and the Trypan Blue dye exclusion assay coupled to the Countess cell counter 
(Invitrogen) following manufacturer’s instructions, after FLAG-gankyrin/mock transfection, incubation with 
cjoc42 or DMSO vehicle and DNA damage with 0.2 μM Etoposide. All assays were performed in triplicate, and 
the data were normalised to vehicle-treated control cells.
Western blotting. Whole cell lysates were subjected to SDS-PAGE and proteins transferred onto polyvi-
nylidene fluoride membranes. The following primary antibodies were used: Gankyrin and p53-DO1 (Santa Cruz 
Biotech), p21and β -actin (Abcam, Cambridge, UK). Secondary HRP-conjugated antibodies were from Dako. 
Luminograms were obtained with Chemiluminescence Detection kits (GE Healthcare, Uppsala, Sweden, Thermo 
Scientific), and the densitometry of the blots was performed using ImageJ software31.
qPCR experiments. Total RNA was extracted from gankyrin over-expressing U2OS cells treated with 1 μM 
cjoc42 or DMSO (control) for 48 hours using the RNeasy Mini kit (Qiagen). Relative mRNA transcript levels were 
measured in triplicate using the Lightcycler 480 Sybr Green 1 kit and the LightCycler(Roche), following reverse 
transcription of 1 μg total RNA. Primers were obtained from Qiagen (Quantitect primers). p53 expression levels 
were assessed in terms of the threshold cycle (Ct) using GAPDH as the housekeeping gene for comparison.
Control experiments. Potential disruption of the RAD51-BRC4 and Aurora A-TPX2 PPIs by cjoc42 was 
analyzed using fluorescence polarization, as described elsewhere32. cjoc42 was tested in human osteosarcoma cells 
(U2OS) for its effect on cell proliferation and for its ability to induce mitotic arrest (the latter assay uses a high con-
tent screening approach wherein cells are stained with an antibody against the mitotic marker phospho-Histone 
H3 (pH3) that allowed a calculation of the percentage of mitotic cells), as described previously32.
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